Predictive biomarkers of chemotherapy-induced peripheral neuropathy: a review

Papers of special note have been highlighted as: • of interest

References

• 1 de Weger VA, Beijnen JH, Schellens JHM. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review. Anticancer Drugs 25(5), 488–494 (2014).
  Medline CASGoogle Scholar
• 2 Jabir RS, Naidu R, Annuar MABA, Ho GF, Munisamy M, Stanslas J. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 13(16), 1979–1988 (2012).
  CASGoogle Scholar
• 3 Hershman DL, Weimer LH, Wang A et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res. Treat. 125(3), 767–774 (2011).
  Medline CASGoogle Scholar
• 4 Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol. 82(1), 51–77 (2012).
  MedlineGoogle Scholar
• 5 von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 73(4), 638–652 (2012).
  Medline CASGoogle Scholar
• 6 Berretta M, Nasti G, Diviitis CDE et al. Safety and efficacy of oxaliplatin-based chemotherapy in the first line treatment of elderly patients affected by metastatic colorectal cancer. WCRJ 1(2), 1–10 (2014).
  Google Scholar
• 7 WHO, International programme on chemical safety. Biomarkers in risk assessment: validity and validation. www.inchem.org/documents/ehc/ehc/ehc222.htm.
  Google Scholar
• 8 Nalejska E, Maczyska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol. Diagnosis Ther. 18(3), 273–284 (2014).
  Medline CASGoogle Scholar
• 9 Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 12(12), 1151–1161 (2011). • Review of the pharmacogenomic and neurological data on chemotherapy induced peripheral neuropathy.
  Medline CASGoogle Scholar
• 10 Seretny M, Currie GL, Sena ES et al. Incidence, prevalence and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12), 2461–2470 (2014). • Meta-analysis of predictive biomarkers of chemotherapy induced peripheral neuropathy.
  MedlineGoogle Scholar
• 11 Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10(1), 54–61 (2010).
  Medline CASGoogle Scholar
• 12 Flanagan JM, Wilhelm-Benartzi CS, Metcalf M, Kaye SB, Brown R. Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. Ann. Oncol. 24(11), 2813–2818 (2013).
  Medline CASGoogle Scholar
• 13 Baldwin R, Owzar K, Zembutsu H et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 18(18), 5099–5109 (2012).
  Medline CASGoogle Scholar
• 14 Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar H-J, Boven E. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. Br. J. Cancer 115(11), 1–8 (2016).
  MedlineGoogle Scholar
• 15 Beutler AS, Kulkarni AA, Kanwar R et al. Sequencing of Charcot–Marie–Tooth disease genes in a toxic polyneuropathy. Ann. Neurol. 76(5), 727–737 (2014).
  Medline CASGoogle Scholar
• 16 Schneider BP, Lai D, Shen F et al. Charcot–Marie–Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget 7(50), 82244–82253 (2016).
  MedlineGoogle Scholar
• 17 Sundar R, Jeyasekharan AD, Pang B et al. Low levels of NDRG1 in nerve tissue are predictive of severe paclitaxel-induced neuropathy. PLoS ONE 11(10), 1–8 (2016).
  Google Scholar
• 18 Inada M, Sato M, Morita S et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int. J. Clin. Pharmacol. Ther. 48(11), 729–34 (2010).
  Medline CASGoogle Scholar
• 19 Ruzzo A, Graziano F, Galli F et al. Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the Phase III TOSCA trial in high-risk colon cancer patients. Sci. Rep. 4, 6828 (2014).
  Medline CASGoogle Scholar
• 20 Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 15(12), 1565–1574 (2014).
  CASGoogle Scholar
• 21 Abraham JE, Guo Q, Dorling L et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin. Cancer Res. 20(9), 2466–2475 (2014).
  Medline CASGoogle Scholar
• 22 Leskelä S, Jara C, Leandro-García LJ et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 11(2), 121–129 (2011).
  Medline CASGoogle Scholar
• 23 Hertz DL, Roy S, Jack J et al. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res. 145(1), 245–254 (2014).
  CASGoogle Scholar
• 24 Hertz DL, Motsinger-Reif AA, Drobish A et al. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res. Treat. 134(1), 401–410 (2012).
  Medline CASGoogle Scholar
• 25 Boora GK, Kanwar R, Kulkarni AA et al. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med. 5(4), 631–639 (2016).
  Medline CASGoogle Scholar
• 26 de Graan A-JM, Van Der Holt B, De Raaf PJ, De Bruijn P, Engels FK. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin. Cancer Res. 19(12), 3316–3324 (2013).
  Medline CASGoogle Scholar
• 27 Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res. 12(10), 3050–3056 (2006).
  Medline CASGoogle Scholar
• 28 Oldenburg J, Kraggerud SM, Brydøy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J. Transl. Med. 5(1), 70 (2007).
  MedlineGoogle Scholar
• 29 Mir O, Alexandre J, Tran A et al. Relationship between GSTP1 Ile 105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann. Oncol. 20(4), 736–740 (2009).
  Medline CASGoogle Scholar
• 30 Chen YC, Tzeng CH, Chen PM et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 101(2), 530–535 (2010).
  Medline CASGoogle Scholar
• 31 Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK. Docetaxel-induced neuropathy: a pharmacogenetic case–control study of 150 women with early-stage breast cancer. Acta Oncol. 54(4), 530–537 (2014).
  MedlineGoogle Scholar
• 32 Kanai M, Kawaguchi T, Kotaka M et al. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (join trial). Ann. Oncol. 27(6), 1143–1148 (2016).
  Medline CASGoogle Scholar
• 33 Peng Z, Wang Q, Gao J et al. Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother. Pharmacol. 72(2), 305–314 (2013).
  Medline CASGoogle Scholar
• 34 Rizzo R, Spaggiari F, Indelli M et al. Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients. Breast Cancer Res. Treat. 124(2), 593–598 (2010).
  Medline CASGoogle Scholar
• 35 Kus T, Aktas G, Kalender M et al. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco. Targets Ther. 9, 5073–5080 (2016).
  Medline CASGoogle Scholar
• 36 Won HH, Lee J, Park JO et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118(11), 2828–2836 (2012).
  Medline CASGoogle Scholar
• 37 Peila E, D'Agata F, Caroppo P et al. Chemotherapy-induced neurotoxicity: evidence of a protective role of cc homozygosis in the interleukin-1β gene-511 C>T polymorphism. Neurotox. Res. 30(3), 521–529 (2016).
  Medline CASGoogle Scholar
• 38 Boora GK, Kulkarni AA, Kanwar R et al. Association of the Charcot–Marie–Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (alliance). J. Neurol. Sci. 357(1–2), 35–40 (2015).
  Medline CASGoogle Scholar
• 39 Sissung TM, Baum CE, Deeken J et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin. Cancer Res. 14(14), 4543–4549 (2008).
  Medline CASGoogle Scholar
• 40 Tanabe Y, Shimizu C, Hamada A et al. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother. Pharmacol. 79(6), 1179–1186 (2017).
  Medline CASGoogle Scholar
• 41 Johnson C, Pankratz VS, Velazquez AI et al. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. 349(0), 124–128 (2016).
  Google Scholar
• 42 Schneider BP, Li L, Radovich M et al. Genome-wide association studies for taxane-induced peripheral neuropathy (TIPN) in ECOG-5103 and ECOG-1199. Clin. Cancer Res. 23(10), 1780–1789 (2016).
  Google Scholar
• 43 Custodio A, Moreno-Rubio J, Aparicio J et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann. Oncol. 25(2), 398–403 (2014).
  Medline CASGoogle Scholar
• 44 Kanai M, Yoshioka A, Tanaka S et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol. 34(2), 189–193 (2010).
  Medline CASGoogle Scholar
• 45 Verhoeven K, De Jonghe P, Van de Putte T et al. Slowed conduction and thin myelination of peripheral nerves associated with mutant Rho guanine-nucleotide exchange factor 10. Am. J. Hum. Genet. 73(4), 926–932 (2003).
  Medline CASGoogle Scholar
• 46 Chaya T, Shibata S, Tokuhara Y et al. Identification of a negative regulatory region for the exchange activity and characterization of T332I mutant of Rho guanine nucleotide exchange factor 10 (ARHGEF10). J. Biol. Chem. 286(34), 29511–29520 (2011).
  Medline CASGoogle Scholar
• 47 Obaishi H, Nakanishi H, Mandai K et al. Frabin, a novel FGD1-related actin filament-binding protein capable of changing cell shape and activating c-Jun N-terminal kinase. J. Biol. Chem. 273(30), 18697–18700 (1998).
  Medline CASGoogle Scholar
• 48 Umikawa M, Obaishi H, Nakanishi H et al. Association of frabin with the actin cytoskeleton is essential for microspike formation through activation of Cdc42 small G protein. J. Biol. Chem. 274(36), 25197–25200 (1999).
  Medline CASGoogle Scholar
• 49 Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 420(6916), 629–635 (2002).
  Medline CASGoogle Scholar
• 50 Delague V, Jacquier A, Hamadouche T et al. Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot–Marie–Tooth type 4h. Am. J. Hum. Genet. 81(1), 1–16 (2007).
  Medline CASGoogle Scholar
• 51 Stendel C, Roos A, Deconinck T et al. Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, Frabin/FGD4. Am. J. Hum. Genet. 81(1), 158–164 (2007).
  Medline CASGoogle Scholar
• 52 Dai D, Zeldin DC, Blaisdell JA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7), 597–607 (2001).
  Medline CASGoogle Scholar
• 53 Soyama A, Saito Y, Hanioka N et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24(12), 1427–1430 (2001).
  Medline CASGoogle Scholar
• 54 Rodríguez-Antona C, Niemi M, Backman JT et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 8(4), 268–277 (2008).
  Medline CASGoogle Scholar
• 55 Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum. Genomics 3(1), 7–16 (2008).
  Medline CASGoogle Scholar
• 56 Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 74(4), 380–387 (2003).
  Medline CASGoogle Scholar
• 57 Niemi M, Backman JT, Kajosaari LI et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77(6), 468–478 (2005).
  Medline CASGoogle Scholar
• 58 Liu H, Shi W, Zhao L, Dai D, Gao J, Kong X. Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports. Onco. Targets Ther. 9, 3683–3694 (2016).
  Medline CASGoogle Scholar